The DOI matches its Crossref record; 214 of the 217 references it cites were found in a registry or an index; 105 of the 281 sources its claims cite were checked for support.
Fibrosis: from mechanisms to medicines
Open accessAbstract
Fibrosis can affect any organ and is responsible for up to 45% of all deaths in the industrialized world. It has long been thought to be relentlessly progressive and irreversible, but both preclinical models and clinical trials in various organ systems have shown that fibrosis is a highly dynamic process. This has clear implications for therapeutic interventions that are designed to capitalize on this inherent plasticity. However, despite substantial progress in our understanding of the pathobiology of fibrosis, a translational gap remains between the identification of putative antifibrotic targets and conversion of this knowledge into effective treatments in humans. Here we discuss the transformative experimental strategies that are being leveraged to dissect the key cellular and molecular mechanisms that regulate fibrosis, and the translational approaches that are enabling the emergence of precision medicine-based therapies for patients with fibrosis.
Overview
CoChat Summary
TL;DR
This review presents fibrosis as a dynamic, plastic tissue-repair outcome across organs rather than an inevitably irreversible process, and it surveys single-cell and mechanistic discoveries that are reshaping antifibrotic target discovery. It also emphasizes that a translational gap still separates promising preclinical mechanisms from effective precision therapies for patients.
Key findings
- Fibrosis can affect any organ and is linked to as much as 45% of deaths in industrialized countries; it results from dysregulated repair after chronic or severe injury, with excessive extracellular matrix accumulation disrupting architecture and organ function.
- Single-cell genomics has uncovered unexpected cellular heterogeneity: over 70,000 multi-lineage cells from 8 human fibrotic lungs and 8 healthy donor lungs revealed a profibrotic alveolar macrophage population; 312,928 cells from 32 IPF, 29 control, and 18 COPD lungs identified IPF-enriched aberrant basaloid epithelial cells; and more than 100,000 human liver cells defined scar-associated TREM2+CD9+ macrophages and ACKR1+/PLVAP+ endothelial subsets.
- Fibroblasts and macrophages show functional diversity and plasticity, including fascia fibroblasts in skin repair, distinct FAPα+THY1+ versus FAPα+THY1− fibroblast subsets in arthritis, and reprogramming of myofibroblasts toward adipocytes or hepatocyte-like cells.
- Candidate therapeutic axes include αv integrin-mediated TGF-β activation, IL-17A/TGF-β and type 2 cytokine pathways, metabolic reprogramming such as glycolysis and glutaminolysis, and microbiome/TLR signaling; several agents have entered phase 2 trials, but no metabolism-targeting antifibrotic has reached the clinic.
Methods
- Narrative review synthesizing mechanistic, preclinical, and clinical literature on fibrosis across multiple organs; no primary experimental data or systematic search strategy is described.
- Evidence discussed includes mouse injury models such as bleomycin-induced lung fibrosis and carbon tetrachloride-induced liver fibrosis, human tissue single-cell RNA sequencing datasets, primary cell/organoid systems, and clinical trial registry identifiers.
- The main analysis is a conceptual synthesis organized around single-cell genomics, fibroblast heterogeneity and plasticity, metabolic regulation, macrophage biology, integrin/TGF-β activation, cytokine networks, microbiome contributions, and future therapeutic directions.
Limitations
- Stated: a translational gap remains between identifying putative antifibrotic targets and producing effective patient therapies; better prognostic animal models and ex vivo human tissue systems are needed, along with validated progression predictors, patient stratification, and more sensitive or clinically meaningful trial endpoints.
- Stated: safety concerns affect some strategies, including systemic TGF-β inhibition, which risks cardiac valve problems, autoimmunity, and carcinogenesis; a selective anti-αvβ6 IPF trial was terminated because of unspecified safety concerns.
- Evident: as a narrative review, it lacks a systematic search strategy, quantitative synthesis, and formal risk-of-bias assessment, so its conclusions rest on selected examples and cited studies rather than a comprehensive evidence appraisal.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
23 Valid · 23 Not valid · 112 Not checked · 12 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Caspase-1, NOD, LRR and pyrin domain-containing (NLRP) 3 inflammasome, and NFkB were identified as important upstream mediators contributing to the activation of the IL-17A-TGF-β axis122”
§ FIBROSIS: FROM MECHANISMS TO MEDICINES > CYTOKINE-MEDIATED REGULATION OF FIBROSIS
What the sources say
- Disputedcites [122] Meng, F. et al. Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology 143, 765–776 (2012). sourceExperimental — accuracy not yet measured
In “Activation of Target Genes in IL-17A Stimulated KC and HSCs” (page unavailable), the paper says IL-17A induces NF-κB activity and explicitly calls NF-κB a downstream target of IL-17 signaling, contrary to the claimed upstream role. Searches for caspase-1 and NLRP3 found no passages identifying them as mediators of the proposed axis. (LLM, conf=0.85)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“A combination of fate mapping and live imaging, revealed that a specialised subset of fibroblasts, fascia fibroblasts, rise to the surface of the skin following wounding26.”
§ FIBROSIS: FROM MECHANISMS TO MEDICINES > FIBROBLAST HETEROGENEITY AND PLASTICITY > Functional fibroblast heterogeneity
What the sources say
- Could not verifycites [26] Ratziu, V. & Friedman, S. L. Why do so many NASH trials fail? Gastroenterology https://doi.org/10.1053/j.gastro.2020.05.046 (2020). sourceExperimental — accuracy not yet measured
Our copy of Ratziu & Friedman (2023) is a Gastroenterology commentary on why NASH antifibrotic trials fail; every passage retrieved concerns hepatic fibrosis, belapectin/galectin-3, rodent cirrhosis models, biopsy readouts and trial design (e.g., pp. on the belapectin case study and on noninvasive markers). Searches for 'fascia fibroblasts fate mapping live imaging skin wounding' and 'dermal fibroblasts wound healing skin' returned only these liver-fibrosis passages, with no mention of skin, fascia fibroblasts or fate mapping. The claim's subject is therefore not addressed by this source at all, and our copy names no alternative work for it, so it is unverifiable rather than disputed or misattributed. (LLM, conf=0.72)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“deletion of fibroblast activation protein-α (FAPα)+ fibroblasts suppressed inflammation and bone erosions in mouse models of resolving and persistent arthritis”
§ FIBROSIS: FROM MECHANISMS TO MEDICINES > FIBROSIS DECONVOLVED BY SINGLE CELL GENOMICS
What the sources say
- Could not verifycites [23] Vento-Tormo, R. et al. Single-cell reconstruction of the early maternal–fetal interface in humans. Nature 563, 347–353 (2018). sourceExperimental — accuracy not yet measured
Our copy of Vento-Tormo et al. (2018) is a human maternal–fetal interface scRNA-seq atlas; it contains no mouse arthritis model, no fibroblast ablation/deletion experiment, and no mention of FAP (fibroblast activation protein). Searches for 'FAP / fibroblast activation protein' and for 'mouse model arthritis bone erosion ablation of fibroblasts' returned only stromal/fibroblast cluster descriptions of decidua and placenta (Stromal cells in the two decidual layers; Extended Data Fig. 4, Fig. 2b) and immunomodulation passages (Immunomodulation during early pregnancy), none of which address the claim. Since our copy simply does not treat this point — and states nothing contrary to it — the claim cannot be verified or disputed here. (LLM, conf=0.75)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Within the vascular endothelial cell compartment an expanded cell population was identified in IPF samples that is transcriptomically identical to vascular endothelial cells normally restricted to the bronchial circulation.”
§ FIBROSIS: FROM MECHANISMS TO MEDICINES > FIBROSIS DECONVOLVED BY SINGLE CELL GENOMICS
What the sources say
- Could not verifycites [9] Tsukui, T. et al. Collagen-producing lung cell atlas identifies multiple subsets with distinct localization and relevance to fibrosis. Nat. Commun. 11, 1920 (2020). sourceExperimental — accuracy not yet measured
Our copy of Tsukui et al. analyses collagen-producing (mesenchymal) cells only: endothelial cells appear merely as one broad population identified by representative markers in the human scRNA-seq (Results, 'scRNA-seq of normal and fibrotic lungs of human'), and the Methods ('Sequencing data processing for human data') state that 'clusters which expressed epithelial and endothelial markers were removed' before further analysis. No passage characterises endothelial subsets, an expanded endothelial population in IPF, or endothelial cells of the bronchial circulation; searches for 'vascular endothelial cells bronchial circulation expanded population IPF', 'bronchial circulation endothelial', 'endothelial cell subset CD31 pulmonary', and 'endothelial cells identified as lineage positive population' returned only fibroblast/pericyte/smooth-muscle material. The IPF stromal expansions the paper does report are pericytes (RGS5+ MCAM+) and CTHRC1+ COL1A1+ fibroblasts, not endothelium, so this claim cannot be checked against this source. (LLM, conf=0.72)
plainn = 29- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Pseudotemporal trajectory and RNA velocity, another computational approach that predicts the future state of individual cells on a timescale, demonstrated that central vein-associated HSCs are the dominant source of pathogenic collagen-producing cells following centrilobular liver injury16.”
§ FIBROSIS: FROM MECHANISMS TO MEDICINES > FIBROSIS DECONVOLVED BY SINGLE CELL GENOMICS
What the sources say
- Partly supportedcites [16] MacParland, S. A. et al. Single cell RNA sequencing of human liver reveals distinct intrahepatic macrophage populations. Nat. Commun. 9, 4383 (2018). sourceExperimental — accuracy not yet measured
The Results section, “Hepatic stellate cells” (page not provided), says activated HSCs lay down collagen-containing extracellular matrix and are major contributors to fibrosis. It does not identify central vein-associated HSCs as the dominant source after centrilobular injury, or report pseudotemporal trajectory or RNA-velocity evidence for that conclusion. (LLM, conf=0.88)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
94 more claims · 31 with their cited sources checked
Create a free account to see all 170 claims and to verify the 176 references still open.
- It may state two separate claims as one. 65
- Probably not a substantial claim. 8
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This regulation occurs directly through cell-cell contact or indirectly via the release of cytokines, chemokines, and ligand-receptor signaling, thereby shaping the trajectory of extracellular matrix deposition and tissue scarring (113).”
From The mechanotransduction-immune axis in organ fibrosis: dual regulatory mechanisms and translational therapeutic perspectives (2025) · doi:10.3389/fimmu.2025.1670213 · cites this paper as [113]
In the citing paper
“Whereas targeting inflammatory cells and blocking their fibrogenic interactions with HSCs seems plausible, targeting the key pro-fibrogenic cytokines – particularly secreted TGFβ – has not yet been successful.114”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [114]
In the citing paper
“Targeting TGF-β directly with antibodies (e.g., fresolimumab or metelimumab) has been largely terminated due to dose-limiting adverse events, since systemic inhibition of the cytokine is immunosuppressive and may promote cancer.114”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [114]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ FIBROSIS: FROM MECHANISMS TO MEDICINES > METABOLIC REGULATION OF MESENCHYMAL CELLS
“Taken together, key metabolic pathways such as increased glycolysis, upregulation of glutaminolysis and enhanced fatty acid oxidation are emerging as important drivers of fibroblast activation.”
§ FIBROSIS: FROM MECHANISMS TO MEDICINES > METABOLIC REGULATION OF MESENCHYMAL CELLS
“Intracellular fatty acid oxidation is downregulated in tubulointerstitial fibrosis in mice and humans, and its restoration was fibroprotective56.”
Citations
Cites
Comprehensive Integration of Single-Cell Data
Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W. M., Hao, Y., Stoeckius, M., Smibert, P., & Satija, R. (2019) · Cell · doi:10.1016/j.cell.2019.05.031 · Cited by 15,453
Integrating single-cell transcriptomic data across different conditions, technologies, and species
Butler, A., Hoffman, P., Smibert, P., Papalexi, E., & Satija, R. (2018) · Nature Biotechnology · doi:10.1038/nbt.4096 · Cited by 13,174
Pattern Recognition Receptors and Inflammation
Takeuchi, O., & Akira, S. (2010) · Cell · doi:10.1016/j.cell.2010.01.022 · Cited by 8,895
Hynes (2002) · doi:10.1016/s0092-8674(02)00971-6 · Cited by 8,606
Aran, D., Looney, A. P., Liu, L., Wu, E., Fong, V., Hsu, A., Chak, S., Naikawadi, R. P., Wolters, P. J., Abate, A. R., et al. (2019) · Nature Immunology · doi:10.1038/s41590-018-0276-y · Cited by 4,984
Macrophages in Tissue Repair, Regeneration, and Fibrosis
Wynn, T. A., & Vannella, K. M. (2016) · Immunity · doi:10.1016/j.immuni.2016.02.015 · Cited by 4,481
Self-citationChronic Inflammation (Inflammaging) and Its Potential Contribution to Age-Associated Diseases
Franceschi, C., & Campisi, J. (2014) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glu057 · Cited by 3,891
Wound repair and regeneration: Mechanisms, signaling, and translation
Eming, S. A., Martin, P., & Tomic-Canic, M. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009337 · Cited by 3,562
Mechanisms of fibrosis: therapeutic translation for fibrotic disease
Wynn, T. A., & Ramalingam, T. R. (2012) · Nature Medicine · doi:10.1038/nm.2807 · Cited by 3,541
Self-citationSimultaneous epitope and transcriptome measurement in single cells
Stoeckius, M., Hafemeister, C., Stephenson, W., Houck-Loomis, B., Chattopadhyay, P. K., Swerdlow, H., Satija, R., & Smibert, P. (2017) · Nature Methods · doi:10.1038/nmeth.4380 · Cited by 3,098
Cited by
CAR T cells produced in vivo to treat cardiac injury
Rurik, J. G., Tombácz, I., Yadegari, A., Méndez Fernández, P. O., Shewale, S. V., Li, L., Kimura, T., Soliman, O. Y., Papp, T. E., Tam, Y. K., et al. (2022) · Science · doi:10.1126/science.abm0594 · Cited by 1,400
Targeting integrin pathways: mechanisms and advances in therapy
Pang, X., He, X., Qiu, Z., Zhang, H., Xie, R., Liu, Z., Gu, Y., Zhao, N., Xiang, Q., & Cui, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01259-6 · Cited by 1,275
CAR T Cells Produced in vivo to Treat Cardiac Injury
Rurik, J. G., Tombácz, I., Yadegari, A., Fernández, P. O. M., Shewale, S. V., Li, L., Kimura, T., Soliman, O. Y., Papp, T. E., Tam, Y. K., et al. (2023) · Book Publisher International (a part of SCIENCEDOMAIN International) · doi:10.9734/bpi/mono/978-81-19039-63-0/ch19 · Cited by 929
Hepatic inflammatory responses in liver fibrosis
Hammerich, L., & Tacke, F. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00807-x · Cited by 803
Wound healing, fibroblast heterogeneity, and fibrosis
Talbott, H. E., Mascharak, S., Griffin, M., Wan, D. C., & Longaker, M. T. (2022) · Cell Stem Cell · doi:10.1016/j.stem.2022.07.006 · Cited by 795
Metadata
- Authors
- Henderson, N. C., Rieder, F., & Wynn, T. A.
- Affiliations
- Centre for Inflammation Research (GB)
- Cleveland Clinic (US)
- Pfizer (United States) (US)
- Corresponding author
- Wynn, Thomas A.
- Venue
- Nature
- Published
- 2020-11-25
- Volume
- 587
- Issue
- 7835
- Pages
- 555-566
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC8034822
- OpenAlex
- W3109793392
- Cited by
- 1,868
- References
- 217
- Citations by year
- 2026: 367 · 2025: 413 · 2024: 407 · 2023: 313 · 2022: 235 · 2021: 131
- FWCI
- 22.62
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- Funders
- Wellcome Trust (219542/Z/19/Z)
- Crohn's and Colitis Foundation (569125)
- British Heart Foundation (RM/17/3/33381, RE/18/5/34216)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK123233, K08DK110415, P30DK097948, T32DK083251)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- fibrosis, antifibrotic therapy, single-cell profiling, precision medicine, translational research, fibrosis mechanisms
- MeSH terms
- Gastrointestinal Microbiome, Fibroblasts, Fibrosis, Humans, Macrophages, Mesoderm, Genome, Human, Integrins, Cytokines, Transforming Growth Factor beta, Translational Research, Biomedical, Precision Medicine, Single-Cell Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fibrosis: from mechanisms to medicines. https://app.cochat.ai/papers/10.1038/s41586-020-2938-9
- The paper
- Henderson, N. C., Rieder, F., & Wynn, T. A. (2020). Fibrosis: from mechanisms to medicines. Nature. https://doi.org/10.1038/s41586-020-2938-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.